within Pharmacolibrary.Drugs.ATC.G;

model G03FA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 1.0,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Norethisterone and estrogen are combined hormonal preparations used for hormone replacement therapy (HRT) in postmenopausal women and previously also in contraception. Norethisterone is a synthetic progestogen, while estrogen in such combinations is commonly estradiol or ethinylestradiol. These combinations alleviate menopausal symptoms and prevent osteoporosis. Such combined HRT regimens are approved and used in many countries today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult women after oral administration, based on typical literature values for norethisterone and estradiol or ethinylestradiol separately, as no published studies provide a combined PK model for the combination product.</p><h4>References</h4><ol><li><p>Wellington, K, &amp; Perry, CM (2002). Estradiol valerate/dienogest. <i>Drugs</i> 62(3) 491–506. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200262030-00006&quot;>10.2165/00003495-200262030-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11827562/&quot;>https://pubmed.ncbi.nlm.nih.gov/11827562</a></p></li><li><p>McClamrock, HD, &amp; Adashi, EY (1993). Pharmacokinetics of desogestrel. <i>American journal of obstetrics and gynecology</i> 168(3 Pt 2) 1021–1028. DOI:<a href=&quot;https://doi.org/10.1016/0002-9378(93)90332-d&quot;>10.1016/0002-9378(93)90332-d</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8447355/&quot;>https://pubmed.ncbi.nlm.nih.gov/8447355</a></p></li><li><p>Vose, CW, et al., &amp; Serlin, MJ (1979). Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. <i>Contraception</i> 19(2) 119–127. DOI:<a href=&quot;https://doi.org/10.1016/s0010-7824(79)80024-4&quot;>10.1016/s0010-7824(79)80024-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/428229/&quot;>https://pubmed.ncbi.nlm.nih.gov/428229</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03FA01;
